Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00799240 · ClinicalTrials.gov registry record · Phase 2
MK-0646 Insulin Growth Factor 1 Receptor Antibody in Stage IIIb or IV Metastatic Non-Squamous Lung Cancer
A Phase 2 study, sponsored by University of Kansas.
- Completed
- Registry status
- Phase 2
- Development phase
- 27
- Enrollment target
NCT00799240 is a Phase 2 study that has completed, run by University of Kansas. The registered enrollment target is 27 participants.
The verdict
NCT00799240, a Phase 2 study, has completed, sponsored by University of Kansas.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 27 participants
- Enrollment target
Study Summary
This study will compare the rate of chemotherapy: pemetrexed and cisplatin compared with the combination of pemetrexed/cisplatin with MK-0646. The other purposes are to determine how long we can control the cancer growth and toxicity and safety of the combination. Laboratory research with the tumor tissue and blood obtained will be done to assess IGF-1R expression and related markers and correlate with response and survival.
Interventions
- DRUG Arm A: Pemetrexed Cisplatin
- DRUG Arm B Pemetrexed, Cisplatin and MK-0646
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 27 participants |
| Start Date | 2009-06 |
| Est. Completion | 2014-07 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00799240
The ClinicalTrials.gov registry entry for NCT00799240 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 27 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Kansas, which has 66 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Arm A: Pemetrexed Cisplatin is the first listed.
NCT00799240 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00799240 about?
NCT00799240 is a clinical study titled "MK-0646 Insulin Growth Factor 1 Receptor Antibody in Stage IIIb or IV Metastatic Non-Squamous Lung Cancer". This study will compare the rate of chemotherapy: pemetrexed and cisplatin compared with the combination of pemetrexed/cisplatin with MK-0646. The other purposes are to determine how long we can control the cancer growth and toxicity and safety of the combination. Laboratory research with the tumor ...
What is the current status of trial NCT00799240?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 27 participants. The study started on 2009-06. Estimated completion is 2014-07.
What interventions are being tested in trial NCT00799240?
The interventions under investigation include: Arm A: Pemetrexed Cisplatin (DRUG), Arm B Pemetrexed, Cisplatin and MK-0646 (DRUG).
Who is sponsoring clinical trial NCT00799240?
This trial is sponsored by University of Kansas, which has 66 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.